Skip to main content
Caplight Logo









Bionic Sight, Inc.

Bionic Sight, Inc.

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.bionicsightllc.com/

Last Round

VC Round

Apr 1, 2025

Est. Valuation

$40M

Company Overview

Bionic Sight, Inc. is a biotechnology company developing optogenetic gene therapies and neuro-prosthetic devices to restore sight to patients with retinal degenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Medical Devices

Business Model

B2B2C

Customer Profile

Revenue Share, Hardware + Subscription, Government Contracts

AI Layer

Non-AI

Keywords

optogenetic gene therapyvision restorationretinal degenerative diseaseretinitis pigmentosabionic eyeartificial visionoptogeneticsgene therapyneural codingmutation-agnostic therapyretinal prosthesiswearable medical deviceclinical-stage biotechRegenerative Medicine Advanced TherapyRMATgeographic atrophy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Bionic Sight, Inc. Comparables

Compare Bionic Sight, Inc. with similar companies based on industry and business-model similarity.

Bionic Sight, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ray Therapeutics
88%
Nanoscope Therapeutics Inc.
86%
SparingVision
83%

Bionic Sight, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundApr 1, 2025
VC RoundJan 24, 2017

Bionic Sight, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2025

    Raised capital from Partnership Fund for New York City.

  • Jan 24, 2017

    $2M round led by Beacon Therapeutics.

Bionic Sight, Inc. Filings

Explore SEC and related filing metadata, where available.

Bionic Sight, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Bionic Sight, Inc.'s valuation, stock price, and market status.

Is Bionic Sight, Inc. a public or private company?

Bionic Sight, Inc. is a private company.

What is the current stock price of Bionic Sight, Inc.?

Bionic Sight, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Bionic Sight, Inc. worth (valuation)?

Bionic Sight, Inc.'s valuation is estimated at $40.0M based on funding round data.

Can I buy Bionic Sight, Inc. stock?

Bionic Sight, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Bionic Sight, Inc.'s last funding round?

Bionic Sight, Inc.'s most recent funding round was VC Round on January 24, 2017.

Who are the main investors in Bionic Sight, Inc.?

Key investors in Bionic Sight, Inc. include The Raptor Group, Partnership for New York City, Cornell University, Samsara BioCapital.

Will Bionic Sight, Inc. IPO soon?

No public IPO plans have been announced for Bionic Sight, Inc..

How can I track Bionic Sight, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Bionic Sight, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew York City, New York
Year Founded2012
Last FundingApr 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?